English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background The majority of hemodialysis patients are affected by the cardiovascular calcification. Vascular/valvular calcification contributes to an extremely high cardiovascular morbidity and mortality in HD patients. Objective To asses circulating levels of Scl in ESRD patients receiving HD and their relation to aortic and mitral valve calcification detected by echocardiography as well. Patients and Methods The study included 80 ESRD patients undergoing HD in Al-Sahel Nephrology and Dialysis unit. Routine chemical investigations, serum sclerostin by ELISA were done to all patients, as well a trans-thoracic Echocardiography. Results serum Scl level ranged from 0.41 ng\ml to 1.65 ng\ml. calcification was documented in 53/80 (66.2%) of our HD patients: 26/80 had aortic valve calcification only(32.5%), 6/80 patients (7.5%) had mitral valve calcification alone, while 21/80 of patients had both aortic and mitral valves calcification (26.25%). 27/80 (33.75%) patients had no calcification. We didn’t find any significant correlation between serum Scl level and valvular calcification nor age, sex or HD duration. Conclusion valvular calcification are prevalent in HD population. Serum Scl was not associated with valvular calcification.

Evaluation of serum sclerostin level and its correlation with valvular calcification in haemodialysis patients